Dogwood Therapeutics Inc. (DWTX)
DWTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | DWTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001818844 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, substantial doubt exists regarding our ability to continue as a going concern 12 months from the issuance of this Quarterly Report on Form 10-Q." | 10-Q 2026-11-06 |
| Cash and burn | $4.9M cash; operating cash flow -$4.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 38,227,913 (2026-11-03); 2,293,162 a year earlier; 19,257,937 three years earlier. 3y figure adjusted for split (1-for-25 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-10-09 | Source 2024-10-09 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-01-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Forvis Mazars, LLP, Atlanta, Georgia, United States | PCAOB Form AP 2026-04-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $100K | -$4.9M | -$4.6M | $4.9M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | -$11.5M | -$3.6M | $9.6M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q1 2026 2026-03-31 | Not filed | -$5.0M | -$4.6M | $13.2M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2025 2025-12-31 | Not filed | -$3.8M | -$3.6M | $6.5M | No debt tags | Needs four quarters | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | Not filed | -$15.7M | -$3.3M | $10.1M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$3.8M | -$4.0M | $13.4M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q1 2025 2025-03-31 | Not filed | -$10.9M | -$4.7M | $17.5M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q4 2024 2024-12-31 | Not filed | -$7.7M | -$6.1M | $14.8M | No debt tags | Needs four quarters | 10-K 2026-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-10-30 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 332 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.3% |
| 1 month | -14.6% |
| 3 months | -43.9% |
| Year to date | -73.3% |
| 1 year | -79.7% |
| From 52-week high | -83.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limited | $0.6430 | -5.05% | $40.5M |
| ALDX | Aldeyra Therapeutics Inc. | $0.6696 | +4.01% | $40.4M |
| GANX | Gain Therapeutics Inc. | $0.9402 | -9.60% | $41.9M |
| ELTX | Elicio Therapeutics Inc. | $1.48 | -1.33% | $41.9M |
| IBO | Impact BioMedical Inc. | $4.91 | -4.47% | $42.4M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier